AI Article Synopsis
- Esophageal squamous cell carcinoma (ESCC) is a prevalent type of digestive tumor, and previous research indicated that the protein eIF3b promotes its progression, though the specific mechanisms were unclear.
- Using quantitative proteomics, the study identified that the expression of Testis-expressed protein 9 (TEX9) is positively correlated with eIF3b, and further experiments confirmed that TEX9 and eIF3b work together to enhance ESCC cell growth, migration, and reduce cell death.
- The research revealed that the interaction between TEX9 and eIF3b activates the AKT signaling pathway, suggesting that targeting these proteins could lead to new therapeutic strategies for treating ESCC.
Article Abstract
Background: Esophageal squamous cell carcinoma (ESCC) is one of the most frequent malignant digestive tumors around the world. We previously demonstrated that eIF3b could promote the progression of ESCC. The exact mechanisms underlying these effects remained unknown.
Methods: Quantitative proteomics was applied to detect the potential targets of Eukaryotic translation initiation factor 3 subunit b (eIF3b). RT-qPCR and Western blot were performed to detect the expression of targeted gene and pathway related genes. RNA-immunoprecipitation was applied to verify the binding of eIF3b with targeted gene. Moreover, CCK-8 assay, colony-formation assay, transwell assay, flow cytometry for cell apoptosis and tumor xenograft assay were performed to analyze the regulation of the targeted gene on the bio-function of ESCC cells.
Results: Quantitative proteomics data showed that Testis-expressed protein 9 (TEX9) expression was positively associated with eIF3b expression. RT-qPCR and Western blot results confirmed the quantitative proteomics data and demonstrated that TEX9 expression was positively correlated with TNM stage in ESCC. Furtherly, RNA-immunoprecipitation confirmed that eIF3b binding to TEX9 mRNA. The bio-function related assay demonstrated that TEX9 and eIF3b functionally synergized to promote the proliferation and migration, and inhibited the apoptosis of ESCC cells. In the analysis of mechanism, we revealed that TEX9 and eIF3b promoted the progression of ESCC through the activation of AKT signaling pathway.
Conclusions: The synergized promoting role of TEX9 and eIF3b in the progression of ESCC may provide a novel mechanism for exploring viable therapeutic strategies for ESCC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6724304 | PMC |
| http://dx.doi.org/10.1186/s12885-019-6071-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
TEX9 and eIF3b functionally synergize to promote the progression of esophageal squamous cell carcinoma.
BMC Cancer
September 2019
Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Article Synopsis
- Esophageal squamous cell carcinoma (ESCC) is a prevalent type of digestive tumor, and previous research indicated that the protein eIF3b promotes its progression, though the specific mechanisms were unclear.
- Using quantitative proteomics, the study identified that the expression of Testis-expressed protein 9 (TEX9) is positively correlated with eIF3b, and further experiments confirmed that TEX9 and eIF3b work together to enhance ESCC cell growth, migration, and reduce cell death.
- The research revealed that the interaction between TEX9 and eIF3b activates the AKT signaling pathway, suggesting that targeting these proteins could lead to new therapeutic strategies for treating ESCC.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!